Difluorodeoxycytidine (dFdC) - gemcitabine: A phase I study

Investigational New Drugs

Volumn 10, Issue 3, 1992, Pages 165-170

  Poplin, Elizabeth A ^a   Corbett, Thomas ^a   Flaherty, Lawrence ^a   Tarasoff, Peter ^b   Redman, Bruce G ^a   Valdivieso, Manuel ^a   Baker, Laurence ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Lilly Corporation ^*  (United States)

Author keywords

difluorodeoxycytidine; gemcitabine; phase I study

Indexed keywords

CYTIDINE DERIVATIVE; GEMCITABINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; HUMAN; INFUSIONS, INTRAVENOUS; MIDDLE AGE; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026441565     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/BF00877241     Document Type: Article

References (14)

1. Phase I study of gemcitabine (diFluorodeoxycytidine; dFdC; (LY188011) administered in a two-weekly schedule
2. A phase I trial of gemcitabine (LY188011) administered IV every two weeks
3. Phase I trial and immunologie assessment of difluorodeoxycytidine
4. Phase II trial of gemcitabine (2′2′-difluorodeoxycytidine) in patients with pancreatic cancer
5. Phase II study of gemcitabine in non small cell lung cancer (NSCLC)
6. A phase I clinical plasma and cellular pharmacology study of gemcitabine
7. Antitumor activity of 2′2′ difluorodeoxycytidine (LY188011)
8. Cellular distribution of gemcitabine (LY188011)
9. Comparison of the cellular pharmacokinetics and toxicity of 2′2′ difluorodeoxycytidine and 1 β D-Arabinofurosylcytosine
10. Evaluation of the antitumor activity of Gemcitabine, (difluor-2′-deoxycytidine)
11. Reporting results of cancer treatment